Amicus Therapeutics (FOLD) shares were down 11% in recent trading on Thursday after the company announced its Q1 results.
The company reported Q1 non-GAAP earnings of $0.03 per diluted share, compared with a loss of $0.02 a year earlier.
Analysts polled by FactSet expected EPS of $0.08.
Net product revenue for the quarter ended March 31 was $125.2 million, up from $110.4 million a year earlier. Analysts expected $135.9 million.
The company reduced its projection for 2025 revenue growth to a range of 15% to 22% from the previously provided range of 17% to 24%.
Price: 6.88, Change: -0.81, Percent Change: -10.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.